Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel P Haas

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
International Urology and Nephrology|August 15, 2013
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilitiesNing Wu, Thomas S Marshall, Luke Boulanger, et al.
JSLS : Journal of the Society of Laparoendoscopic Surgeons|July 16, 2025
Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354)Chris Atzinger, Heather Dickerson, Ela Polek, et al.
Anticancer Research|May 4, 2005
Comparison of ante- and post-mortem PSA levels for epidemiological studiesRichard F Jones, Robert Sunheimer, Henry Friedman, et al.
Anticancer Research|November 27, 2008
Occult prostate cancer effects the results of case-control studies due to verification biasTaro Iguchi, Ching Y Wang, Nicolas B Delongchamps, et al.
The Journal of Urology|April 12, 2005
Higher than expected association of clinical prostate and bladder cancersAmar Singh, Yoshihisa Kinoshita, Peter M Rovito, et al.
The Journal of Urology|April 25, 2008
Higher than expected association of clinical prostate and bladder cancersAmar Singh, Yoshihisa Kinoshita, Peter M Rovito, et al.
Urology|June 24, 2008
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control groupTaro Iguchi, Ching Y Wang, Nicolas B Delongchamps, et al.
Clinical and Translational Science|February 4, 2022
Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transportersSrinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, et al.
The Journal of Urology|March 18, 2008
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?Nicolas B Delongchamps, Gustavo de la Roza, Vishal Chandan, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
International Urology and Nephrology|August 15, 2013
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilitiesNing Wu, Thomas S Marshall, Luke Boulanger, et al.
JSLS : Journal of the Society of Laparoendoscopic Surgeons|July 16, 2025
Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354)Chris Atzinger, Heather Dickerson, Ela Polek, et al.
Anticancer Research|May 4, 2005
Comparison of ante- and post-mortem PSA levels for epidemiological studiesRichard F Jones, Robert Sunheimer, Henry Friedman, et al.
Anticancer Research|November 27, 2008
Occult prostate cancer effects the results of case-control studies due to verification biasTaro Iguchi, Ching Y Wang, Nicolas B Delongchamps, et al.
The Journal of Urology|April 12, 2005
Higher than expected association of clinical prostate and bladder cancersAmar Singh, Yoshihisa Kinoshita, Peter M Rovito, et al.
The Journal of Urology|April 25, 2008
Higher than expected association of clinical prostate and bladder cancersAmar Singh, Yoshihisa Kinoshita, Peter M Rovito, et al.
Urology|June 24, 2008
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control groupTaro Iguchi, Ching Y Wang, Nicolas B Delongchamps, et al.
Clinical and Translational Science|February 4, 2022
Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transportersSrinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, et al.
The Journal of Urology|March 18, 2008
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?Nicolas B Delongchamps, Gustavo de la Roza, Vishal Chandan, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Pageof 9